IDEXX Laboratories, Inc.
IDXXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, IDEXX Laboratories, Inc. (IDXX) is listed under Diagnostics & Research. The $44.76B market capitalization puts IDXX squarely in large-cap range for its industry. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Market Cap
$44.76B
Beta
1.55
P/E (TTM)
42.38
P/E (Fwd)
34.36
EPS (TTM)
$13.39
EPS (Fwd)
$16.52
ROE
72.9%
ROA
26.5%
Cash
$200.5M
Total Debt
$1.11B
Free CF
$786.8M
52W Change
10.3%
Annual Financials
Cash vs Debt
The company holds $200.5M in cash, though total debt stands at $1.11B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $786.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 72.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 26.5% further supports the picture of efficient asset utilization. Revenue has grown from $3.37B (2022) to $4.30B (2025), reflecting a 28% increase over the period.
A beta of 1.55 means IDXX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence IDEXX Laboratories, Inc.'s trajectory.